Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOD001 Open-Label Extension in AL Amyloidosis
NCT03154047Phase 2Terminated
- Sponsor
- Prothena Corporation
- Start
- Jun 2017
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of birtamimab in amyloid light chain amyloidosis, sponsored by Prothena Corporation. Started Jun 2017; status: terminated.
02
Drugs
birtamimab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT03154047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154047.